Solid Biosciences (SLDB) CFO reports PSU, RSU vesting and tax sale
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Solid Biosciences CFO & Treasurer Kevin Tan reported multiple equity transactions. On January 29, 2026, 56,646 performance stock units converted one-for-one into common stock, increasing his directly held common shares to 102,746. That same day he received an employee stock option for 187,000 shares vesting over four years and a new grant of 93,500 restricted stock units, also vesting over four years.
On January 31, 2026, 33,075 restricted stock units from a prior 2025 grant vested and converted into common stock, lifting his direct holdings to 135,821 shares. On February 2, 2026, he sold 26,837 shares at a weighted average price of $6.4369 solely to cover withholding taxes under a pre-arranged automatic sell-to-cover instruction, leaving 108,984 common shares held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 26,837 shares ($172,747)
Net Sell
7 txns
Insider
Tan Kevin
Role
CFO & Treasurer
Sold
26,837 shs ($173K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 26,837 | $6.4369 | $173K |
| Exercise | Restricted Stock Units | 33,075 | $0.00 | -- |
| Exercise | Common Stock | 33,075 | $0.00 | -- |
| Exercise | Performance Stock Units | 56,646 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Buy) | 187,000 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 93,500 | $0.00 | -- |
| Exercise | Common Stock | 56,646 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 108,984 shares (Direct);
Restricted Stock Units — 99,225 shares (Direct);
Performance Stock Units — 0 shares (Direct);
Employee Stock Option (Right to Buy) — 187,000 shares (Direct)
Footnotes (1)
- Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis. Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis. This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Tan on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Tan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares. This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary. The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary. On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 132,300 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.
FAQ
What insider transactions did SLDB CFO Kevin Tan report on this Form 4?
Kevin Tan reported PSU and RSU vesting, new equity grants, and a tax-related share sale. Performance stock units and restricted stock units converted into common shares, new options and RSUs were granted, and a portion of shares was sold to cover withholding taxes under an automatic instruction.
What new stock options did the Solid Biosciences CFO receive in January 2026?
On January 29, 2026, the CFO received an option covering 187,000 shares of common stock. The option vests over four years, with 25% vesting on the first anniversary of the 2026 grant date and 2.0833% monthly thereafter until the fourth anniversary.
What restricted stock unit grants are disclosed for the SLDB CFO?
The CFO received 93,500 RSUs on January 29, 2026 and previously 132,300 RSUs on January 31, 2025. Both RSU awards vest in four equal annual installments, with 25% vesting on each anniversary of their respective grant dates, subject to continued service.
How did performance stock units affect the SLDB CFO’s common stock holdings?
On January 29, 2026, 56,646 performance stock units converted one-for-one into common stock. This vesting followed certification that the first performance milestone was achieved, increasing his directly held common shares before later transactions reported in the same Form 4.